Effects of β‐blockers on all‐cause mortality in patients with type 2 diabetes and coronary heart disease

AIMS: To assess whether the use of beta‐blockers influences mortality and the incidence of major cardiovascular events in patients with diabetes and coronary heart disease (CHD). MATERIALS AND METHODS: Using data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial, we performed Cox proportional hazards analysis to assess the effects of β‐blockers on all‐cause mortality in 2244 patients with type 2 diabetes who had stable CHD with and without a history of myocardial infarction (MI)/heart failure with reduced left ventricular ejection fraction (HFrEF). RESULTS: All‐cause mortality in patients with MI/HFrEF was significantly lower in those receiving β‐blockers than in those not receiving β‐blockers (adjusted hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.37‐0.98; P = .04), whereas that in patients without MI/HFrEF did not significantly differ (adjusted HR 0.91, 95% CI 0.76‐1.32; P = .64). Among patients with MI/HFrEF, all‐cause mortality in those who received intensive medical therapy alone for CHD was significantly lower in those on β‐blockers than in those not on β‐blockers (adjusted HR 0.45, 95% CI 0.23‐0.88; P = .02); however, mortality in patients who received early revascularization for CHD was not significantly lower in those on β‐blockers (adjusted HR 0.81, 95% CI 0.40‐1.65; P = .57). The risk of major cardiovascular events in patients without MI/HFrEF was not significantly different between those on and those not on β‐blocker treatment. CONCLUSIONS: In patients with diabetes and CHD, the use of β‐blockers was effective in reducing all‐cause mortality in those with MI/HFrEF but not in those without MI/HFrEF.